SenoRx, Inc. has announced the launch of an additional model of its SenoSonix System, EnCor breast biopsy system with ultrasound imaging. This novel device incorporates a microminiaturization ultrasound technology that combines personal computing power and flexibility. The ultrasound component is designed, developed and manufactured by Terason, a division of Teratech Corporation. This novel and flexible ultrasound technology coupled with company's proprietary EnCor vacuum-assisted biopsy technology results in an attractive alternative model of the SenoSonix System. The modular design and sophisticated imaging architecture are now available in a reduced footprint with increased portability. The SenoSonix System received 510(k) clearance in October 2007 and CE Mark approval in April 2008. "Our new SenoSonix model is designed to meet the needs of breast surgeons performing breast biopsy procedures utilizing ultrasound in both their offices and in the hospital surgery suite who wish to have the flexibility of moving the ultrasound component between the two locations," said Lloyd Malchow, SenoRx President and Chief Executive Officer. "The new system may be particularly well suited for markets in Europe and Asia where a significant percentage of biopsy procedures are performed utilizing ultrasound. We are pleased to be working with Terason on this compact portable solution. We will begin introducing this product in the US and in select countries in which we have launched the EnCor breast biopsy system." "We are happy to be partnering with SenoRx on this new initiative," said Dr. Alice Chiang, Terason Chief Executive Officer. "SenoRx is a leader in their market segment and, like Terason, has been innovative in enhancing patient care using ultrasound image guidance."